Skip to main content
Signal8

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

$BLRXPress releaseJul 8, 2026, 7:00 AM ETRead the release

BioLineRx and partner Hemispherian announced positive preclinical data demonstrating strong synergy between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The combination therapy showed tumor reduction comparable to the chemotherapy benchmark cisplatin and outperformed monotherapy arms, supporting the synthetic lethality mechanism in HR-proficient tumors.

Key figures

Drug Name
GLIX1
Trial id
NCT07464925
Trial phase
Phase 1/2a
Hr proficient tumor pct
50%
Ovarian cancer cases 2026
approximately 21,000
Ovarian cancer deaths 2026
12,450

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.